These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16578966)

  • 1. [Inhibitory effect of human saliva on HIV-1 infectivity].
    Etsuko K; Wei S
    Nihon Rinsho Meneki Gakkai Kaishi; 2001 Aug; 24(4):152-9. PubMed ID: 16578966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.
    McNeely TB; Dealy M; Dripps DJ; Orenstein JM; Eisenberg SP; Wahl SM
    J Clin Invest; 1995 Jul; 96(1):456-64. PubMed ID: 7615818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory function of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and varies with virus tropism.
    Skott P; Lucht E; Ehnlund M; Björling E
    Oral Dis; 2002 May; 8(3):160-7. PubMed ID: 12108760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous salivary inhibitors of human immunodeficiency virus.
    Shugars DC; Alexander AL; Fu K; Freel SA
    Arch Oral Biol; 1999 Jun; 44(6):445-53. PubMed ID: 10401522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I.
    Shugars DC; Sauls DL; Weinberg JB
    Oral Dis; 1997 May; 3 Suppl 1():S70-2. PubMed ID: 9456661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients.
    Baqui AA; Meiller TF; Falkler WA
    Clin Diagn Lab Immunol; 1999 Nov; 6(6):808-11. PubMed ID: 10548568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I.
    Wahl SM; McNeely TB; Janoff EN; Shugars D; Worley P; Tucker C; Orenstein JM
    Oral Dis; 1997 May; 3 Suppl 1():S64-9. PubMed ID: 9456660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of HIV infectivity by human saliva.
    Malamud D; Nagashunmugam T; Davis C; Kennedy S; Abrams WR; Kream R; Friedman HM
    Oral Dis; 1997 May; 3 Suppl 1():S58-63. PubMed ID: 9456659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and viral infectivity.
    Foda M; Harada S; Maeda Y
    Microbiol Immunol; 2001; 45(7):521-30. PubMed ID: 11529558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous mucosal antiviral factors of the oral cavity.
    Shugars DC
    J Infect Dis; 1999 May; 179 Suppl 3():S431-5. PubMed ID: 10099113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues.
    Wahl SM; Worley P; Jin W; McNeely TB; Eisenberg S; Fasching C; Orenstein JM; Janoff EN
    Am J Pathol; 1997 Apr; 150(4):1275-84. PubMed ID: 9094984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids.
    Kazmi SH; Naglik JR; Sweet SP; Evans RW; O'Shea S; Banatvala JE; Challacombe SJ
    Clin Vaccine Immunol; 2006 Oct; 13(10):1111-8. PubMed ID: 16928883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral transmission of HIV, reality or fiction? An update.
    Campo J; Perea MA; del Romero J; Cano J; Hernando V; Bascones A
    Oral Dis; 2006 May; 12(3):219-28. PubMed ID: 16700731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk.
    Farquhar C; VanCott TC; Mbori-Ngacha DA; Horani L; Bosire RK; Kreiss JK; Richardson BA; John-Stewart GC
    J Infect Dis; 2002 Oct; 186(8):1173-6. PubMed ID: 12355371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity.
    Jana NK; Gray LR; Shugars DC
    J Virol; 2005 May; 79(10):6432-40. PubMed ID: 15858026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the oral environment in HIV-1 transmission.
    Shugars DC; Wahl SM
    J Am Dent Assoc; 1998 Jul; 129(7):851-8. PubMed ID: 9685760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivary secretory leukocyte protease inhibitor increases in HIV infection.
    Lin AL; Johnson DA; Stephan KT; Yeh CK
    J Oral Pathol Med; 2004 Aug; 33(7):410-6. PubMed ID: 15250833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro inhibition of HIV-1 infectivity by human salivas.
    Archibald DW; Cole GA
    AIDS Res Hum Retroviruses; 1990 Dec; 6(12):1425-32. PubMed ID: 2078420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secretory leukocyte protease inhibitor (SLPI): oxidation of SLPI does not explain its variable anti-HIV activity.
    Konopka K; Shine N; Pretzer E; Düzgüneş N
    J Dent Res; 1999 Dec; 78(12):1773-6. PubMed ID: 10598905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 infectivity and host range modification by cathepsin D present in human vaginal secretions.
    El Messaoudi K; Thiry L; Van Tieghem N; Liesnard C; Englert Y; Moguilevsky N; Bollen A
    AIDS; 1999 Feb; 13(3):333-9. PubMed ID: 10199223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.